Coronary Artery Lesions

June 01, 2017
1158706
Heart
Gregory Giugliano, MD
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
The purpose of this study is to check the safety of 3-month dual antiplatelet therapy (DAPT) in patients at high risk of bleeding (HBR) with the approved XIENCE family of coronary drug-eluting stents.
  • At least 18 years of age
  • History of major bleeding
  • History of stroke
12 months
Recruiting
Annette Scarnici
413-794-9076